Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
S. Palacios. (2022) Medical treatment of osteoporosis. Climacteric 25:1, pages 43-49.
Read now
Read now
Articles from other publishers (42)
John A. Eisman, Bernard Cortet, Mitra Boolell, Raluca Ionescu-Ittu, Francis Vekeman, Julie Heroux & Friederike Thomasius. (2023) Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Osteoporosis International 34:5, pages 977-991.
Crossref
Crossref
Fanouria-Eirini G. Alatzoglou, Maria Vassaki, Kalliopi Nirgianaki, Eleftherios Tripodianos, Petri Turhanen, Konstantinos D. Demadis & Konstantinos E. Papathanasiou. (2023) Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate. Materials 16:9, pages 3379.
Crossref
Crossref
Antonio Ruggiero, Silvia Triarico, Alberto RomanoPalma Maurizi, Giorgio Attina & Stefano Mastrangelo. (2023) Bisphosphonates: From Pharmacology to Treatment. Biomedical and Pharmacology Journal 16:1, pages 221-229.
Crossref
Crossref
Anjali Pant, Joga Singh, Ravi Pratap Barnwal, Gurpal Singh & Bhupinder Singh. (2023) Theranostic Approach for the Management of Osteoporosis. Critical Reviews™ in Therapeutic Drug Carrier Systems 40:3, pages 95-121.
Crossref
Crossref
Stephen J I Shearan, Enrico Andreoli & Marco Taddei. (2022) An alternative C–P cross-coupling route for the synthesis of novel V-shaped aryldiphosphonic acids. Beilstein Journal of Organic Chemistry 18, pages 1518-1523.
Crossref
Crossref
Nicholas Fuggle, Nasser Al-Daghri, Olivier Bock, Jaime Branco, Olivier Bruyère, Enrique Casado, Etienne Cavalier, Bernard Cortet, Maarten de Wit, Andrea Giusti, Philippe Halbout, Nicholas C. Harvey, Mickaël Hiligsmann, Jean-Marc Kaufman, Andreas Kurth, Stefania Maggi, Radmila Matijevic, Salvatore Minisola, Santiago Palacios, Régis Pierre Radermecker, Friederike Thomasius, Sansin Tuzun, Nicola Veronese, John A. Kanis, Jean-Yves Reginster, René Rizzoli & Cyrus Cooper. (2022) Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research 34:11, pages 2625-2634.
Crossref
Crossref
Jesús González Macías & José Manuel Olmos Martínez. (2022) Aminobisfosfonatos: reconsideración a los 25 años de su aprobación para el tratamiento de la osteoporosis. Medicina Clínica 159:7, pages 336-343.
Crossref
Crossref
Jesús González Macías & José Manuel Olmos Martínez. (2022) Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis. Medicina Clínica (English Edition) 159:7, pages 336-343.
Crossref
Crossref
Diane Kleinermans, Andrew Joyson & Heather Wray. (2022) An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate. Pharmacology Research & Perspectives 10:3.
Crossref
Crossref
María Begoña Coco Martín, Luis Leal Vega, José Antonio Blázquez Cabrera, Amalia Navarro, María Jesús Moro, Francisca Arranz García, María José Amérigo, Manuel Sosa Henríquez, María Ángeles Vázquez, María José Montoya, Manuel Díaz Curiel, José Manuel Olmos, José Luis Pérez Castrillón, José Filgueira Rubio, Pilar Sánchez Molini, José María Aguado Caballero, Dolors Armengol Sucarrats, María Luz Calero Bernal, Begoña de Escalante Yanguas, Nerea Hernández de Sosa, José Luis Hernández, Julia Jareño Chaumel, María José Miranda García, Mercedes Giner García, Cristina Miranda Díaz, Rafael Cotos Canca, Juan Carlos Cobeta García, Francisco Javier Rodero Hernández & Raimundo Tirado Miranda. (2022) Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry. Aging Clinical and Experimental Research 34:9, pages 1997-2004.
Crossref
Crossref
Monika Zielińska, Grzegorz Garbacz, Jaroslaw Sczodrok & Adam Voelkel. (2022) The Effects of Various Food Products on Bisphosphonate’s Availability. Pharmaceutics 14:4, pages 717.
Crossref
Crossref
Hermizi Hapidin, Nor Munira Hashim, Mohamad Zahid Kasiram & Hasmah Abdullah. (2022) The Effects of Polyphenol, Tannic Acid, or Tannic Acid in Combination with Pamidronate on Human Osteoblast Cell Line Metabolism. Molecules 27:2, pages 451.
Crossref
Crossref
Friederike Thomasius, Santiago Palacios, Asif Alam, Mitra Boolell, Francis Vekeman & Geneviève Gauthier. (2021) Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Osteoporosis International 33:1, pages 217-228.
Crossref
Crossref
Maliha Afroj Zinnia & Abul Bashar Mir Md. Khademul Islam. (2021) Fenugreek steroidal saponins hinder osteoclastogenic bone resorption by targeting CSF-1R which diminishes the RANKL/OPG ratio. International Journal of Biological Macromolecules 186, pages 351-364.
Crossref
Crossref
Stefano Pluda, Riccardo Beninatto, Matteo Soato, Carlo Barbera, Alba di Lucia, Lidia Fassina, Filippo Gatti, Cristian Guarise, Devis Galesso & Mauro Pavan. (2021) Hyaluronic acid-alendronate conjugate: A macromolecular drug delivery system for intra-articular treatment of osteoarthritis. Osteoarthritis and Cartilage Open 3:2, pages 100159.
Crossref
Crossref
Anthony R. Martin, Jay M. Patel, Ryan C. Locke, Michael R. Eby, Kamiel S. Saleh, Matthew D. Davidson, Mackenzie L. Sennett, Hannah M. Zlotnick, Andrew H. Chang, James L. Carey, Jason A. Burdick & Robert L. Mauck. (2021) Nanofibrous hyaluronic acid scaffolds delivering TGF-β3 and SDF-1α for articular cartilage repair in a large animal model. Acta Biomaterialia 126, pages 170-182.
Crossref
Crossref
Agnieszka Wiesner, Mariusz Szuta, Agnieszka Galanty & Paweł Paśko. (2021) Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness—A Concise Literature Review. Foods 10:4, pages 720.
Crossref
Crossref
Yanting Hou, Hongyu Piao, Yoshiro Tahara, Shouhong Qin, Jingying Wang, Qingliang Kong, Meijuan Zou, Gang Cheng & Masahiro Goto. (2020) Solid-in-oil nanodispersions as a novel delivery system to improve the oral bioavailability of bisphosphate, risedronate sodium. European Journal of Pharmaceutical Sciences 155, pages 105521.
Crossref
Crossref
Maurício Palmeira Chaves de Souza, Rafael Miguel Sábio, Tais de Cassia Ribeiro, Aline Martins dos Santos, Andréia Bagliotti Meneguin & Marlus Chorilli. (2020) Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems. International Journal of Biological Macromolecules 159, pages 804-822.
Crossref
Crossref
Remzi Bahşi, Volkan Atmiş, Tuğba Turgut, Deniz Mut Sürmeli, Çağlar Coşarderelioğlu, Hande Selvi Öztorun, Ahmet Yalçin, Sevgi Aras & Murat Varli. (2019) May zoledronic acid have negative effects on cognition and muscle performance?. Irish Journal of Medical Science (1971 -) 189:1, pages 191-196.
Crossref
Crossref
Deepak Kumar Khajuria, Ramakrishna Vasireddi, Manish Kumar Priydarshi & Debiprosad Roy Mahapatra. (2019) Ionic Diffusion and Drug Release Behavior of Core–Shell-Functionalized Alginate–Chitosan-Based Hydrogel. ACS Omega 5:1, pages 758-765.
Crossref
Crossref
Omar A. Elkady, Mina Ibrahim Tadros & Hanan M. El-laithy. (2019) QbD Approach for Novel Crosslinker-Free Ionotropic Gelation of Risedronate Sodium–Chitosan Nebulizable Microspheres: Optimization and Characterization. AAPS PharmSciTech 21:1.
Crossref
Crossref
Satoshi Soen, Hideaki Kishimoto, Hiroshi Hagino, Teruki Sone, Hiroaki Ohishi, Tsukasa Fujimoto, Emma Sasaki, Sakae Tanaka & Toshitsugu Sugimoto. (2019) Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis. Journal of Bone and Mineral Metabolism 38:1, pages 86-98.
Crossref
Crossref
Mary Demarest Litchford. 2020. Integrative and Functional Medical Nutrition Therapy. Integrative and Functional Medical Nutrition Therapy
213
220
.
V. A. Rumyantsev, D. R. Avakova & A. V. Blinova. (2019) Host response modulation in periodontology and implantology: potential of anti-inflammatory, antibacterial therapy and promising dosage forms. Review. Periodontology 24:4, pages 372-377.
Crossref
Crossref
Dhrubojyoti Mukherjee, Bharath Srinivasan, Jayaraman Anbu, Md. Azamthulla, B. Venkatesh Teja, S.G. Ramachandra, Krishnaveni. N & Avinash Lakkawar. (2019) Pamidronate functionalized mucoadhesive compact for treatment of osteoporosis-in vitro and in vivo characterization. Journal of Drug Delivery Science and Technology 52, pages 915-926.
Crossref
Crossref
Patrice Fardellone, Stefano Lello, Antonio Cano, Eloisa de Sá Moreira, Renato Watanabe de Oliveira, Guilherme Silva Julian & Boxiong Tang. (2019) Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clinical Therapeutics 41:8, pages 1576-1588.
Crossref
Crossref
Sonia Teixeira, Luis Branco, Maria H. Fernandes & João Costa-Rodrigues. (2019) Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects. Mini-Reviews in Medicinal Chemistry 19:12, pages 988-998.
Crossref
Crossref
Mirko Koziolek, Stefano Alcaro, Patrick Augustijns, Abdul W. Basit, Michael Grimm, Bart Hens, Caroline L. Hoad, Philipp Jedamzik, Christine M. Madla, Marc Maliepaard, Luca Marciani, Annalisa Maruca, Neil Parrott, Petr Pávek, Christopher J.H. Porter, Christos Reppas, Diana van Riet-Nales, Jari Rubbens, Marina Statelova, Natalie L. Trevaskis, Kateřina Valentová, Maria Vertzoni, Dubravka Vitali Čepo & Maura Corsetti. (2019) The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences 134, pages 31-59.
Crossref
Crossref
Stephen J.I. Shearan, Norbert Stock, Franziska Emmerling, Jan Demel, Paul A. Wright, Konstantinos D. Demadis, Maria Vassaki, Ferdinando Costantino, Riccardo Vivani, Sébastien Sallard, Inés Ruiz Salcedo, Aurelio Cabeza & Marco Taddei. (2019) New Directions in Metal Phosphonate and Phosphinate Chemistry. Crystals 9:5, pages 270.
Crossref
Crossref
Shruti Nagaraja & Serge Ankri. (2019) Target identification and intervention strategies against amebiasis. Drug Resistance Updates 44, pages 1-14.
Crossref
Crossref
Konstantinos E. Papathanasiou, Maria Vassaki, Argyro Spinthaki, Fanouria-Eirini G. Alatzoglou, Eleftherios Tripodianos, Petri Turhanen & Konstantinos D. Demadis. (2019) Phosphorus chemistry: from small molecules, to polymers, to pharmaceutical and industrial applications. Pure and Applied Chemistry 91:3, pages 421-441.
Crossref
Crossref
Yeeun Cho, Seunghoon Lee, Jihye Kim, Jung Won Kang, Yong-Hyeon Baek, Byung-Kwan Seo & Jae-Dong Lee. (2018) The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Trials 19:1.
Crossref
Crossref
Ranya Elsayed, Pheba Abraham, Mohamed E. Awad, Zoya Kurago, Balasudha Baladhandayutham, Gary M. Whitford, David H. Pashley, Charles E. McKenna & Mohammed E. Elsalanty. (2018) Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. Bone 110, pages 141-149.
Crossref
Crossref
Blessing Aderibigbe, Isiaka Aderibigbe & Patricia Popoola. (2016) Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics 9:4, pages 2.
Crossref
Crossref
Racquel Jandoc, Muhammad Mamdani, Linda E. Lévesque & Suzanne M. Cadarette. (2016) Urban–rural differences in the uptake of new oral bisphosphonate formulations. Archives of Osteoporosis 11:1.
Crossref
Crossref
Marcin Magierowski, Katarzyna Magierowska, Jakub Szmyd, Marcin Surmiak, Zbigniew Sliwowski, Slawomir Kwiecien & Tomasz Brzozowski. (2016) Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury. Digestive Diseases and Sciences 61:11, pages 3176-3189.
Crossref
Crossref
M.L. Guzman, E.A. Soria, C. Laino, R.H. Manzo & M.E. Olivera. (2016) Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics 107, pages 263-272.
Crossref
Crossref
Michael Pazianas & Bo Abrahamsen. (2016) Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?. Annals of the New York Academy of Sciences 1376:1, pages 5-13.
Crossref
Crossref
Jeong S. Kim, Sun W. Jang, Miwon Son, Byoung M. Kim & Myung J. Kang. (2016) Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. European Journal of Pharmaceutical Sciences 82, pages 45-51.
Crossref
Crossref
R. Graham G. Russell, Maria K. Tsoumpra, Michelle A. Lawson, Andrew D. Chantry, Frank H. Ebetino & Michael Pazianas. 2016. The Duration and Safety of Osteoporosis Treatment. The Duration and Safety of Osteoporosis Treatment
17
36
.
R Graham G Russell. (2015) Pharmacological diversity among drugs that inhibit bone resorption. Current Opinion in Pharmacology 22, pages 115-130.
Crossref
Crossref